Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study

LJJ Scheres, MPA Brekelmans, W Ageno, C Ay, HR Bülle, S Eichinger, BA Hutten, FA Klok, S Middeldorp, K Schreiber, K Stach, M Blondon, A Delluc

1 Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
2 Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands
3 Department of Thrombosis and Hemostasis, University of Insubria, Varese, Italy
4 Department of Medicine I Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
5 Department of Medicine I, Medical University of Vienna, Vienna, Austria
6 Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands
7 Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
8 Thrombosis & Thrombophilia, Guy’s and St Thomas’ Hospital NHS Foundation Trust, London, UK
9 Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
10 1st Medical Department, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany
11 Division of Angiology and Haemostasis, Department of Specialties of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
12 Department of Internal Medicine and Chest Diseases, Center Hospitalier Universitaire de Brest, Hôpital de la Cavale Blanche, Brest, France
13 Correspondence: LJJ Scheres, Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands. Email: l.j.scheres@amc.uva.nl

Accepted 31 May 2018. Published Online 20 July 2018.

Objective To investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE).

Design and setting Post hoc analysis of the Hokusai-VTE study, a multicentre, randomised, double-blind trial comparing edoxaban with warfarin for acute symptomatic VTE.

Population Women below 50 years receiving edoxaban or warfarin for treatment of VTE.

Methods We collected data on diagnostic measures, treatment, and clinical outcome of abnormal vaginal bleeding events.

Main outcome measures Occurrence of major and clinically relevant nonmajor (CRNM) abnormal vaginal bleeding events.

Results In all, 628 women aged under 50 years were treated with edoxaban and 665 with warfarin. The rate of abnormal vaginal bleeding was 15/100 person-years (py) (95% CI 11–19) in women receiving edoxaban and 9/100 py (95% CI 6–12) in the warfarin group (hazard ratio: 1.7, 95% CI 1.1–2.5). Major abnormal vaginal bleeding occurred in eight (1.3%) women on edoxaban and in three (0.9%) women receiving warfarin [odds ratio (OR) 2.8; 95% CI 0.8–10.8], and CRNM abnormal vaginal bleeding occurred in 53 (8.4%) women treated with edoxaban and in 37 (5.6%) on warfarin therapy (OR 1.6, 95% CI 1.0–2.4). Over 85% of all vaginal bleeds were characterised by heavy menstrual bleeding. Major bleeds frequently required treatment, and in more than 75% of patients anticoagulant therapy was adjusted. The severity of clinical presentation and course of major and CRNM bleeds was mild in most patients.

Conclusions Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin. Reassuringly, most events could be managed conservatively and had a mild outcome.

Keywords Abnormal uterine bleeding, edoxaban, oral anticoagulants, vaginal bleeding, venous thromboembolism, warfarin.

Tweetable abstract Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin.

Linked article This article is commented on by B Myers, p. 1590 in this issue. To view this mini commentary visit https://doi.org/10.1111/1471-0528.15315.

Please cite this paper as: Scheres LJJ, Brekelmans MPA, Ageno W, Ay C, Bülle HR, Eichinger S, Hutten BA, Klok FA, Middeldorp S, Schreiber K, Stach K, Blondon M, Delluc A. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. BJOG 2018;125:1581–1589.

*Both authors contributed equally to the contents of this manuscript.
Introduction

Direct oral anticoagulants (DOACs) are at least as effective as vitamin K antagonists (VKA) for the treatment of venous thromboembolism (VTE) and cause less overall bleeding.\textsuperscript{1,2} In addition, DOACs are user-convenient and can be administered in a fixed-dose regimen without the necessity for regular laboratory monitoring. As a result, DOACs have been rapidly implemented in guidelines and routine clinical practice as the first choice of anticoagulants for the treatment of VTE.\textsuperscript{3}

Although the risk of major bleeding, especially intracranial haemorrhage, is lower with DOAC than with VKA therapy,\textsuperscript{1} several studies have reported an increased incidence of abnormal vaginal bleeding events in women of reproductive age treated with rivaroxaban and apixaban, compared with warfarin.\textsuperscript{4–9} The most frequently reported symptoms were heavy and prolonged menstrual bleeding.\textsuperscript{5,8} The severity of the bleeds varied widely, from mild discomfort to distinct anaemia to life-threatening bleeding requiring immediate intervention to stop the bleeding.\textsuperscript{5,7–9}

In the previously published Hokusai-VTE study, a randomised double-blind placebo controlled trial, edoxaban was compared with warfarin in patients with symptomatic VTE.\textsuperscript{10} Whether edoxaban is also associated with increased risks of abnormal vaginal bleeding is unknown, as only a few cases have been described.\textsuperscript{7,8} Therefore, we aimed to investigate the occurrence, characteristics, diagnostic measures, treatment, and clinical outcome of abnormal vaginal bleeding events in women of reproductive age receiving treatment with edoxaban or warfarin for VTE in the Hokusai-VTE study.\textsuperscript{10}

Methods

Study population

The Hokusai-VTE study

Data for the present analyses were obtained from an in-depth analysis of the Hokusai-VTE study, a multicentre, randomised, double-blind, double-dummy trial comparing edoxaban with warfarin in patients with acute, symptomatic VTE (ClinicalTrials.gov identifier: NCT00986154).\textsuperscript{10} Patients from both groups received initial treatment with enoxaparin or unfractionated heparin, with a target INR of 2.0–3.0. The minimal treatment duration was 3 months with a maximum of 12 months at the discretion of the treating physician. Patients were excluded from the study if they had any of the following: any contraindications for treatment with edoxaban or warfarin, active cancer with long-term treatment with heparin anticipated, continued treatment with aspirin in a daily dose of 100 mg or higher or dual antiplatelet therapy, a creatinine clearance below 30 ml/min. Full information on inclusion and exclusion criteria is detailed in the original publication of the Hokusai-VTE study.\textsuperscript{10}

The principal safety outcome was the occurrence of clinically relevant bleeding events [a combination of major and clinically relevant nonmajor (CRNM) bleeding]. All bleeding events were recorded in standardised case report forms. The protocol did not specify the treatment options for bleeding events, but appropriate diagnostic and laboratory work-up was required.\textsuperscript{10} Suspected outcomes were adjudicated by an independent committee whose members were unaware of study treatment allocation. The study protocol was reviewed and approved by the institutional medical ethical review board at each participating centre and all patients provided written informed consent.\textsuperscript{10}

Patient involvement

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

Current study population and design

For the current analysis, we included all women aged under the age of 50 years. Two independent investigators (M.P.B. and L.J.S.) who were unaware of treatment allocation, collected the following data for all abnormal vaginal bleeding events that occurred during the study period: characteristics of the vaginal bleeding event [duration, severity (major or CRNM bleeding), frequency, relation to menstrual cycle], applied diagnostic tests, medical interventions, procedures or treatment to control the bleeding, and severity of clinical presentation and clinical course of the event. Data were obtained from case report forms, bleeding narratives, and patient profiles. Bleeding events were included if they occurred during the treatment period (when patients were receiving the study drug or within 3 days after discontinuation or interruption of the study drug).

Classification abnormal uterine bleeding

We used the definitions of the International Federation of Gynaecology and Obstetrics (FIGO)\textsuperscript{11} further to categorise abnormal vaginal bleeding as: prolonged, intermenstrual or...
heavy menstrual bleeding, or menstrual bleeding leading to anaemia or an unscheduled evaluation by a physician, the need for a medical or surgical intervention, or temporary or permanent interruption of the study drug.

**Classification of clinical presentation and clinical course**
The clinical presentation and course of all major and CRNM abnormal vaginal bleeding events were classified by two independent clinicians (M.P.B. and L.J.S.) using predefined criteria (Supporting Information Table S1), as previously described. In short, the first classification assessed the severity of the abnormal vaginal bleeding event at the moment of presentation. In the second classification, the course and outcome of the bleeding event were evaluated. If the assessors were in doubt between two categories of the classification scheme, the more severe outcome was chosen.

**Statistical analysis**
We used the independent sample t-test and Mann–Whitney U test to compare normally distributed and not normally distributed continuous variables, respectively, and the chi-square test to compare categorical variables.

A Cox proportional hazard regression analysis was performed to compare abnormal vaginal bleeding rates between the women treated with edoxaban and warfarin. The outcome was defined as major or CRNM vaginal bleeding. Observation time started at the time of randomisation and ended at the time of a first abnormal vaginal bleed. If a vaginal bleed did not occur, participants were censored at the last day of study drug use plus 3 days, or at the end of follow up. The absolute incidence of vaginal bleeds was calculated by dividing the number of events by observation time, with Poisson-based 95% confidence intervals (95% CI). The Cox model was adjusted for dose adjustments, site of VTE (deep vein thrombosis versus pulmonary embolism with or without deep vein thrombosis), and provoked versus unprovoked VTE.

Logistic regression models were constructed to estimate odds ratios (OR) and 95% CI for the occurrence of major and/or CRNM abnormal vaginal bleeding events in the different treatment groups (edoxaban versus warfarin). Analyses were carried out using SPSS 24 for Windows (IBM Software, Armonk, NY, USA).

**Results**

**Study population**
Among the 8292 patients who participated in the Hokusai-VTE study, 1293 were women and aged below 50 years. Of these, 628 (49%) were treated with edoxaban and 665 (51%) with warfarin. There were no differences in baseline characteristics between these two groups (Supporting Information Table S2).

Supporting Information Figure S1 provides an overview of all major and CRNM bleeding events that occurred in this subgroup of the Hokusai-VTE study. The overall incidence rate of abnormal vaginal bleeding was 15/100 py (95% CI 11–19) with edoxaban and 9/100 py (95% CI 6–12) with warfarin (hazard ratio 1.7, 95% CI 1.1–2.5; see Figure 1 for the Kaplan–Meier curve).

The baseline characteristics of all women aged under 50 years with a major or CRNM abnormal vaginal bleeding in the Hokusai-VTE study are depicted in Table 1. There were no apparent differences in the baseline characteristics between the edoxaban and warfarin groups. The time from randomisation to the bleeding event was similar in both groups with a median of 42 days [interquartile range (IQR) 24–96] for women treated with edoxaban and 36 days (IQR 20–117) for women receiving warfarin. Approximately 10% of women in both groups had a prior gynaecological disorder. One-third of the women receiving edoxaban or warfarin used hormonal contraceptives at the moment of randomisation.

**Major bleeds**
Major abnormal vaginal bleeding occurred in eight (1.3%) of 628 women on edoxaban and in three (0.9%) of 665 women in the warfarin arm (OR 2.8, 95% CI 0.8–10.8).

**Characteristics**
All major abnormal vaginal bleeding events were classified as abnormal uterine bleeding according to the FIGO

![Failure Probability](image)

**Figure 1.** Kaplan–Meier curve for on-treatment abnormal vaginal bleeding in women aged under 50 years in the Hokusai-VTE trial treated with edoxaban or warfarin. The outcome includes both major abnormal vaginal bleeding and clinically relevant nonmajor abnormal vaginal bleeding. The blue line indicates treatment with edoxaban and the red line treatment with warfarin. Numbers in blue and red indicate women at risk during the study for edoxaban and warfarin, respectively.

© 2018 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists
criteria (Table 2); all bleeds in both groups were characterised as heavy menstrual bleeding and required an unscheduled contact with a physician. Anaemia was common in both groups. Prolonged and intermenstrual bleeding seemed to occur more frequently in women receiving edoxaban, although these differences did not reach statistical significance.

Diagnostic measures and treatment
Diagnostic tests were performed in four major bleeds on edoxaban and one of those on warfarin (Table 2). Uterine myomas were the underlying cause in two women on edoxaban and one woman on warfarin.

Of the abnormal vaginal bleeds in both treatment arms, 10 of 11 women required hospital admission. Packed cell transfusions were given to three edoxaban users and two warfarin recipients. None of the women received treatment with oral or intrauterine contraceptives. Radiological or surgical interventions were performed in three major bleeds

**Table 1.** Baseline characteristics of women less than 50 years of age with a major or CRNM abnormal vaginal bleeding in the Hokusai-VTE trial

|                                | Edoxaban | Warfarin |
|--------------------------------|----------|----------|
| **Age (years), median (IQR)**   | 42 (35–46) | 42 (35–45) |
| **BMI (kg/m²), median (IQR)**   | 29 (25–34) | 28 (24–32) |
| **Randomisation to bleeding (days), median (IQR)** | 42 (24–102) | 36 (20–117) |
| **Index event, n (%)**          |          |          |
| DVT                            | 35 (57)  | 24 (60)  |
| PE                             | 22 (36)  | 12 (30)  |
| Both                           | 4 (7)    | 4 (10)   |
| **Risk factors for VTE, n (%)** |          |          |
| Active cancer                  | 1 (2)    | 0        |
| Known thrombophilia            | 4 (7)    | 0        |
| Previous VTE                   | 11 (18)  | 3 (8)    |
| Immobilisation                 | 15 (25)  | 8 (20)   |
| Use of estrogen-containing drugs| 20 (33)  | 13 (33)  |
| Other                          | 8 (13)   | 7 (18)   |
| None                           | 20 (33)  | 16 (40)  |
| History of anaemia, n (%)       | 26 (43)  | 18 (45)  |
| Prior gynaecological disorder, n (%) | 5 (8) | 4 (10) |
| Antiplatelet use at randomisation, n (%) | 6 (10) | 4 (10) |
| NSAID use at randomisation, n (%)** | 19 (31) | 13 (33) |
| Hormonal contraceptives, n (%)** | 20 (33) | 11 (28) |

BMI, body mass index; DVT, deep vein thrombosis; IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drugs; PE, pulmonary embolism; SD, standard deviation.

*Multiple risk factors may be present.

**Table 2.** Characteristics, diagnostic measures, treatment and outcomes of major abnormal vaginal bleeding events in the Hokusai-VTE trial

|                                | Edoxaban | Warfarin |
|--------------------------------|----------|----------|
| **Number of women with major abnormal vaginal bleeding** | 8 | 3 |
| **Classifying for FIGO criteria AUB, n (%)** | 8 (100) | 3 (100) |
| **Prolonged menstrual bleeding** | 2 | 0 |
| **Intermenstrual bleeding** | 2 | 0 |
| **Heavy menstrual bleeding** | 8 | 3 |
| **Anaemia** | 5 | 2 |
| **Unscheduled contact** | 8 | 3 |
| **Diagnostic tests applied*, n (%)** | 4 (50) | 1 (33) |
| Ultrasonography | 2 | 1 |
| Biopsy | 2 | 1 |
| Hysterectomy | 1 | 0 |
| Unknown | 0 | 0 |
| **Diagnosis, n (%)** | 2 (25) | 3 (100) |
| Uterine myoma | 2 | 1 |
| Endometriosis | 0 | 1 |
| Cervical cancer | 0 | 1 |
| Haematoma | 0 | 0 |
| **Hospital admission, n (%)** | 7 (88) | 3 (100) |
| **Treatment, n (%)** |        |        |
| Transfusion of packed cells | 3 (38) | 2 (67) |
| Iron supplements | 2 (25) | 0 |
| **Hormone therapy** |        |        |
| Estrogen containing | 0 | 0 |
| Progestagen containing | 0 | 0 |
| IUD | 0 | 0 |
| Tranexamic acid | 2 (25) | 0 |
| Unknown | 2 (25) | 1 (33) |
| **No treatment** | 2 (25) | 0 |
| **Radiologic or surgical interventions, n (%)** | 2 (25) | 2 (67) |
| Hysterectomy | 2 (25) | 0 |
| Endometrial ablation or curettage | 1 (12) | 0 |
| No interventions | 5 (63) | 1 (33) |
| Other | 0 | 0 |
| Unknown | 0 | 0 |
| **Change in anticoagulant, n (%)** | 2 (25) | 0 |
| Unchanged | 2 (25) | 0 |
| Temporary interruption | 3 (38) | 3 (100) |
| Permanent stop | 1 (12) | 0 |
| Switch to another anticoagulant | 1 (12) | 0 |
| Adjusted treatment dose | 1 (12) | 0 |
| Unknown | 0 | 0 |
| Life-threatening bleeding – n (%) | 0 | 1 (33) |
| Fatal bleeding – n (%) | 0 | 0 |
| Repetitive bleeding, n (%) | 1 (13) | 0 |
| Recurrent VTE, n (%) | 2 (25) | 0 |
| **Classification of presentation of major vaginal bleed, n (%)** |        |        |
| Category 1 | 3 (38) | 0 |
| Category 2 | 4 (50) | 2 (67) |
| Category 3 | 1 (12) | 1 (33) |
| Category 4 | 0 | 0 |
with edoxaban and in two with warfarin; four of these concerned a hysterectomy. In two major vaginal bleedings with edoxaban, treatment was not deemed necessary (Table 2).

Anticoagulant treatment was unchanged in only two major abnormal vaginal bleedings in edoxaban recipients and in none receiving warfarin. Temporary interruption was deemed necessary in three women on edoxaban and and three women on warfarin. Other changes included permanent discontinuation \((n = 1)\), switch to another anticoagulant \((n = 1)\), and dose adjustment \((n = 3)\) (Table 2).

Clinical presentation, course, and clinical outcome
In the women with a major abnormal vaginal bleed, repetitive bleeding was uncommon, with only one observation in the edoxaban arm. With respect to the severity of the vaginal bleeds, most bleeding events presented as category 1 or 2 and were mild (seven in the edoxaban and two in the warfarin arm). One woman using edoxaban and one woman using warfarin had a category 3 clinical presentation of the major abnormal vaginal bleed. Reassuringly, none of the major bleeds in either group was classified as having a category 3 or 4 clinical course (i.e. severe clinical course).

Clinically relevant nonmajor bleeds
CRNM abnormal vaginal bleeding occurred in 53 (8.4%) of 628 women treated with edoxaban and in 37 (5.6%) of 665 women receiving warfarin (OR 1.6, 95% CI 1.0–2.4). Of the total 80 CRNM bleeds in the edoxaban arm, 53 (66%) were of vaginal origin, whereas of the 68 bleeds in the warfarin arm, this was 37 (55%) (OR 1.6, 95% CI 0.8–3.2; Figure S1).

Characteristics
All but one CRNM bleed in the warfarin arm was classified as abnormal uterine bleeding according to the FIGO criteria (consequently, this bleeding event was not included in further analyses). Most CRNM abnormal vaginal bleeds, 45 (85%) in the edoxaban arm and 32 (89%) in the warfarin arm, were characterised as heavy menstrual bleeding. More CRNM abnormal vaginal bleeds in women treated with edoxaban were associated with anaemia [11 (21%)] compared with in women using warfarin in [6 (2%); Table 3].

Diagnostic measures and treatment
In women receiving edoxaban, diagnostic tests were applied in 10 (19%) patients versus three (8%) women treated with warfarin. In four (40%) edoxaban and in two (67%) warfarin recipients, a cause of the vaginal bleeding could be detected (Table 3). Approximately 10% of patients in both groups required hospital admission for the bleeding event. Medical treatment was not initiated in 31 (58%) edoxaban recipients and in 24 (66%) women on warfarin. The majority of women [51 women (96%) in the edoxaban arm and 34 (94%) in the warfarin arm] did not undergo any radiological or surgical interventions. The anticoagulation remained unchanged in most women: it was temporarily suspended in 12 (22%) edoxaban and in eight (22%) warfarin recipients, and permanently discontinued in two (4%) and one (3%) patients.

Clinical presentation, course, and clinical outcome
In these women with an abnormal vaginal CRMN bleed, repetitive bleeding was frequently observed [28 (53%) edoxaban and 18 (50%) warfarin recipients; Table 3]. The clinical presentation and course of CRNM vaginal bleeds were classified as mild (i.e. category 1 or 2) in 28 (54%) of edoxaban recipients and in 23 (64%) of warfarin recipients.

Discussion
Main findings
Edoxaban is the most recently approved DOAC for the treatment and secondary prevention of VTE.15 As the uptake of edoxaban in clinical practice will likely increase over the following years, there is a need for information on the occurrence, clinical impact, and management of abnormal vaginal bleeding complications related to the use of edoxaban.

In this analysis, abnormal vaginal bleeding occurred frequently (9–15/100 py) and significantly more often in women of reproductive age receiving edoxaban compared with women receiving warfarin. In addition, the risk of major abnormal vaginal bleeding also appeared greater with edoxaban than warfarin, albeit with 95% CI crossing unity. All major bleeds were characterised by heavy menstrual bleeding, and most cases required a treatment or intervention to control the bleeding and resulted in modifications of the anticoagulant treatment. The severity of clinical presentation and course of the major abnormal vaginal bleeds
was mild in most patients and no fatal events were observed. However, hysterectomies were performed in four of 11 women with a major abnormal vaginal bleeding, underlining the potentially serious consequences of these events. Regarding the CRNM bleeds, diagnostic tests and interventions were needed in a minority of the patients, and most women remained on their usual anticoagulant treatment. The severity of clinical presentation and course did not differ between the treatment groups and was mild in more than half of the patients.

**Strengths and limitations**

Strengths of the present analysis are that the Hokusai-VTE study was a double-blind study in which all bleeding events were adjudicated without knowledge of treatment allocation; information on bleeding was collected prospectively on predefined event forms. Another strength is that patients were actively asked about signs and symptoms of bleeding, and therefore the risk of underreporting is low. Several limitations should also be mentioned. The first is the relatively modest sample size. We were able to analyse the occurrence and outcome of the bleeding events in this high-quality data set. However, we cannot rule out that possible differences in characteristics, treatment or outcome between the two treatment groups may not have been detected due to the limited number of events; however, we believe that the risk of confounding in this subgroup analysis remains low. Furthermore, the diagnostic process and applied treatment options were not standardised and were at the discretion of the treating physician. This might have introduced bias, as local hospital protocols or expert opinions may vary. Additionally, no information was available on hormonal contraceptive use during the study period. It would have been informative to know whether women were treated with hormones, which therapies were used, and how this affected important clinical outcomes, such as recurrences, repetitive bleeding, and severity of the bleeds. Currently, only a few studies have been able to investigate the safety of prescribing hormones during the use of anticoagulants, but future studies should confirm these results. Finally, no information was collected on the quality of life of the women with abnormal vaginal bleeding. Data on quality of life are important to assess the impact on the patients’ daily activities, and to guide treatment and management decisions.

**Interpretation**

Several recent studies have shown an increased rate of vaginal bleeding events in women of reproductive age treated with rivaroxaban compared with VKA. The occurrence of abnormal vaginal bleeding varied between 20 and 32% in women receiving rivaroxaban and between 12 and 15% in VKA-treated women. The data for apixaban are

---

**Table 3.** Characteristics, diagnostics, treatment and outcomes of CRNM abnormal vaginal bleeding events in the Hokusai-VTE trial

|                      | Edoxaban | Warfarin |
|----------------------|----------|----------|
| Number of women with CRNM abnormal vaginal bleeding | 53       | 37       |
| Classifying for FIGO criteria AUB, n (%)          | 53 (100) | 36 (97)  |
| Prolonged menstrual bleeding                       | 8        | 5        |
| Intermenstrual bleeding                             | 8        | 2        |
| Heavy menstrual bleeding                             | 45       | 32       |
| Anaemia                                             | 11       | 2        |
| Unscheduled contact                                 | 29       | 14       |
| Diagnostic tests applied*, n (%)                    | 10 (19)  | 3 (8)    |
| Ultrasound                                          | 6        | 3        |
| Biopsy                                             | 0        | 0        |
| Hysteroscopy                                        | 1        | 0        |
| Unknown                                             | 3        | 1        |
| Diagnosis, n (%)                                    | 4 (8)    | 2 (5)    |
| Uterine myoma                                       | 2        | 1        |
| Endometriosis                                       | 0        | 0        |
| Cervical cancer                                     | 2        | 0        |
| Haematoma                                           | 0        | 1        |
| Hospital admission, n (%)                           | 7 (13)   | 4 (11)   |
| Treatment, n (%)                                    |          |          |
| Transfusion of packed cells                         | 2 (4)    | 1 (3)    |
| Iron supplements                                    | 5 (9)    | 1 (3)    |
| Hormone therapy                                     |          |          |
| Estrogen-containing                                 | 1 (2)    | 1 (3)    |
| Progestagen-containing                              | 1 (2)    | 0        |
| IUD                                                 | 0        | 1 (3)    |
| Tranexamic acid                                     | 3 (6)    | 0        |
| Unknown                                             | 10 (19)  | 8 (22)   |
| No treatment                                        | 31 (58)  | 24 (66)  |
| Radiologic or surgical interventions, n (%)         |          |          |
| Hysterectomy                                        | 0        | 1 (3)    |
| Endometrial ablation or curettage                   | 1 (2)    | 0        |
| No interventions                                    | 51 (96)  | 34 (94)  |
| Other                                               | 0        | 1 (3)    |
| Unknown                                             | 1 (2)    | 0        |
| Change in anticoagulant, n (%)                      |          |          |
| Unchanged                                           | 38 (72)  | 25 (69)  |
| Temporary interruption                              | 12 (22)  | 8 (22)   |
| Permanent stop                                      | 2 (4)    | 1 (3)    |
| Switch to another anticoagulant                      | 0        | 0        |
| Adjusted treatment dose                              | 0        | 0        |
| Unknown                                             | 1 (2)    | 2 (6)    |
| Repetitive bleeding, n (%)                          | 28 (53)  | 18 (50)  |
| Recurrent VTE, n (%)                                 | 0        | 0        |
| Classification of CRNM vaginal bleed, n (%)         |          |          |
| Category 1                                          | 18 (34)  | 18 (50)  |
| Category 2                                          | 10 (19)  | 5 (14)   |
| Category 3                                          | 17 (32)  | 10 (28)  |
| Category 4                                          | 7 (13)   | 3 (8)    |
| Unknown                                             | 1 (2)    | 0        |

AUB, abnormal uterine bleeding; CRNM, clinically relevant nonmajor; FIGO, International Federation of Gynaecology and Obstetrics; IUD, intrauterine device; VTE, venous thromboembolism.

*Patients may have undergone multiple diagnostic tests.
Abnormal vaginal bleeding with edoxaban or warfarin

less clear; some studies reported a similar risk of heavy vaginal bleeding for apixaban and VKA, whereas in others, apixaban was associated with an increased risk of excess vaginal bleeding. For edoxaban, only a few cases have been described in the literature, and in our study, the rate of abnormal vaginal bleeds appeared to be higher with edoxaban than with VKA. To date, data on the occurrence and outcome of abnormal vaginal bleeding events associated with the use of dabigatran etexilate, a direct thrombin inhibitor, are scarce. In a conference abstract reporting on a post hoc analysis of the pooled RE-COVER studies, a lower risk of abnormal uterine bleeding was reported with dabigatran etexilate than with warfarin in women aged up to 50 years with VTE. Further detailed observational data are needed to provide more insight into this.

Abnormal vaginal bleeding associated with anticoagulant use in women of reproductive age is frequently related to the menstrual cycle, and may involve prolonged, heavy or intermenstrual bleeding. It decreases quality of life and may impact daily activities. Physicians should be aware of this complication and inform the patients at risk. It is important to encourage patients to seek medical attention in case abnormal vaginal bleeding occurs, to prevent temporary or permanent discontinuation of anticoagulant treatment, leading to an increased risk of recurrent VTE. Several preventive and therapeutic measures are available to manage abnormal vaginal bleeding in women using anticoagulants, although practice patterns are diverse and not in accordance with guideline recommendations. Effective treatment options for excess vaginal bleeding are the placement of an intrauterine device or hormonal contraceptive, and neither are associated with an increased VTE risk during the use of anticoagulants. In addition, intrauterine devices also have been found safe in terms of VTE risk outside of anticoagulant use. Another option is the use of tranexamic acid during the menstrual period; however, its safety profile and efficacy are not well documented in this patient group. Also, one can switch a woman to another DOAC or to VKA, but the reduction in bleeding symptoms of switching is unclear. All DOAC and VKA therapies carry a risk of abnormal vaginal bleeding and, for VKA, several other disadvantages also apply, such as higher rate of intracranial haemorrhages, interactions with other drugs, and the necessity of frequent laboratory controls and dose adjustments. Referral to a gynaecologist should be considered. An assessment and management strategy for women with abnormal vaginal bleeding associated with anticoagulants were suggested recently by Boonyawat et al.

The underlying mechanism of the observed increased risk of abnormal vaginal bleeding with FXa inhibitors is unknown. The use of FXa inhibitors may have a direct effect on the uterine wall, similar to the effect of FXa inhibitors on the gastrointestinal wall and the variable amount of active drug present there, which might induce local bleeding tendency. Also, FXa inhibitors may influence the apparently tightly regulated process of local haemostasis of the uterine wall.

Conclusion

In conclusion, we found that the incidence of abnormal vaginal bleeding events in women under 50 years of age was higher with edoxaban than with warfarin. Almost all abnormal vaginal bleeding events were characterised by heavy menstrual bleeding, and in most cases remained mild with a limited clinical impact. These findings provide reassurance that although vaginal bleeding events are a frequent complication of anticoagulant treatment in women of reproductive age, most events can be managed conservatively and have a mild outcome. Nevertheless, awareness should be increased among physicians and patients to prevent and recognise vaginal bleeding complications early in order to avoid temporary or permanent cessation of anticoagulant treatment.

Disclosure of interests

LJJS, MPAB, BAH, and KS have nothing to disclose. WA reports grants from Bayer and personal fees from Daiichi Sankyo, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, Pfizer, Aspen, Portola, Stago, CSL Behring, Sanofi, outside the submitted work. CA reports personal fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer outside the submitted work. HRB reports grants and personal fees from Daiichi Sankyo, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer outside the submitted work. FAK reports research grants from Bayer, research grants from Bristol-Myers Squibb, research grants from Boehringer-Ingelheim, research grants from MSD, Research grants from Actelion, and non-financial research support from Daiichi-Sankyo outside the submitted work. SM reports grants or research support from GSK/Aspen, BMS/Pfizer, Sanquin, Bayer, and Daiichi Sankyo. Consultant fees from Bayer, BMS/Pfizer, Boehringer Ingelheim and Daiichi Sankyo, Paid Instructor at Bayer, GSK, BMS/Pfizer, Boehringer Ingelheim, Sanofi, and Daiichi Sankyo, outside the submitted work. All fees are paid to her Institution. KS reports grants and personal fees from Daiichi Sankyo, Sanofi, Novartis, Amgen, Berlin Chemie, outside the submitted work. MB reports travelling fees from Daiichi Sankyo, outside the submitted work. AD reports research grants from Bayer, BMS-Pfizer, Boehringer,
Daiichi-Sankyo, Leo Pharma and Portola and travel grants from Bayer, BMS-Pfizer, Boehringer, GSK and Leo Pharma outside the submitted work. Full disclosure of interests available to view online as supporting information.

Contribution to authorship
LJJS, MPAB, WA, CA, HHR, SE, BAH, FK, SM, KS, ST, MBl, and AD were involved in the study conception and planning of the study. LJJS, MPAB, BAH, and HHR carried out the analysis and interpretation of data, and drafting of the manuscript. WA, CA, SE, BAH, FK, SM, KS, ST, MBl, and AD revised the manuscript critically for important intellectual content. LJJS, MPAB, WA, CA, HHR, SE, BAH, FK, SM, KS, ST, MBl, and AD provided final approval of the manuscript submitted.

Details of ethics approval
The protocol of the original Hokusai-VTE study (ClinicalTrials.gov number, NCT00986154) was reviewed and approved by the institutional medical ethical review board at each participating centre and all patients provided written informed consent. A full list of the participating centres is available elsewhere.

Acknowledgements
We thank Min Lin and George Zhang from Daiichi Sankyo Pharma Development, Edison, NJ, USA, for making data of the Hokusai-VTE study available. L.J.J. Scheres is a PhD candidate of the CREW project (2013T083) supported by the Netherlands Heart Foundation. Saskia Middeldorp holds a VIDI Innovative Grant from the Netherlands Organisation for Health Research and Development (NWO, 2012) on Thrombophilia and Reproduction.

Funding
These analyses were performed without financial support. The original Hokusai-VTE study was financed by Daiichi Sankyo.

Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1 All bleeding events in women aged under 50 years in the hokusai-VTE trial.

Table S1 Classification of clinical presentation and course of major and clinically relevant nonmajor bleeding events.

Table S2 Baseline characteristics of all women less than 50 years of age in the Hokusai-VTE study.

References
1 van Es N, Coppen M, Schuitema S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968–75.
2 van der Hulde T, Koopman J, den Exter PL, Dekkers OM, Klok F, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014;12:329–8.
3 Keanon C, Aki EA, Orenelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315–52.
4 Ferreira M, Barsam S, Patel JP, Czupryniska J, Roberts LN, Patel RK, et al. Heavy menstrual bleeding on rivaroxaban. Br J Haematol 2015;173:314–15.
5 De Crem N, Peerlink K, Vanassche T, Vanheule K, Debaveye Y, Middeldorp S, et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res 2015;136:749–53.
6 Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2015;127:1417–25.
7 Beyer-Westendorf J, Michalski F, Tittl L, Hauswald-Dorschel S, Marten S. Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy. Thromb Haemost 2016;115:1234–6.
8 Beyer-Westendorf J, Michalski F, Tittl L, Hauswald-Dorschel S, Marten S. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. Lancet Haematol 2016;3:e480–6.
9 Brekelmans MP, Scheres LJ, Bleker SM, Huten BA, Timmermans A, Buller HR, et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thromb Haemost 2017;117:809–15.
10 Buller HR, Decousus H, Grosso M, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406–15.
11 Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med 2011;29:383–90.
12 Eerenberg ES, Middeldorp S, Levi M, Lensing AW, Buller HR. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemost 2015;13:1590–6.
13 Brekelmans MP, Bleker SM, Bauersachs R, Boda Z, Buller HR, Choi Y, et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost 2016;116:55–61.
14 Bleker SM, Cohen AT, Buller HR, Agnelli G, Gallus AS, Raskob GE, et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLEfY trial. Thromb Haemost 2016;116:1159–64.
15 The US Food and Drug Administration. Highlights of prescribing information. SAVAYSA (edoxaban) tablets for oral use, 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf
16 Cohen H, Arachchilage DR, Beyer-Westendorf J, Middeldorp S, Kadir RA. Direct oral anticoagulants and women. Semin Thromb Hemost 2016;42:789–97.
Abnormal vaginal bleeding with edoxaban or warfarin

17 Kline JA, Kahler ZP, Beam DM. Outpatient treatment of low-risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance. Patient Prefer Adherence 2016;10:561–9.

18 Myers B, Webster A. Heavy menstrual bleeding on Rivaroxaban—comparison with Apixaban. Br J Haematol 2017;176:833–5.

19 Bryk AH, Pirog M, Plens K, Undas A. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism. Vascul Pharmacol 2016;87:242–7.

20 Godin R, Marcoux V, Tagalakis V. Abnormal uterine bleeding in women receiving direct oral anticoagulants for the treatment of venous thromboembolism. Vascul Pharmacol 2017;93–95:1–5.

21 Ferreira MKF, Feuring M, Fraessdorf M, Kreuzer J, Huismann MV. Abstract: dabigatran is associated with a significantly lower risk of abnormal uterine bleeding than warfarin in female patients of childbearing age with venous thromboembolism. Blood 2016;128:140.

22 Singh S, Best C, Dunn S, Leyland N, Wolfman WL. Abnormal uterine bleeding in pre-menopausal women. J Obstet Gynaecol Can 2013;35:473–5.

23 Klok FA, Schreiber K, Stach K, Ageno W, Middeldorp S, Eichinger S, et al. Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey. Thromb Res 2017;153:101–7.

24 van Hylckama VA, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010;30:2297–300.

25 Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001;86:714–15.

26 Sundstrom A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 2009;116:91–7.

27 Boonyawat K, O’Brien SH, Bates SM. How I treat heavy menstrual bleeding associated with anticoagulants. Blood 2017;130:2603–9.

28 Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Haemost 2014;112:918–23.

29 Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants—defining the issues and the management strategies. Thromb Haemost 2013;110:205–12.

30 Davies J, Kadir RA. Endometrial haemostasis and menstruation. Rev Endocr Metab Disord 2012;13:289–99.

31 Supplement to: The Hokusa-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406–15.